Brimonidine tartrate gel plus topical steroid for the prevention of laser therapy-related postinflammatory hyperpigmentation

被引：3

作者：

Hong, Ji Yeon ^{[1
]}

Lee, Hae Woong ^{[2
]}

Park, Kui Young ^{[1
]}

Kim, Beom Joon ^{[1
]}

Kim, Myeung Nam ^{[1
]}

机构：

[1] Chung Ang Univ, Dept Dermatol, Coll Med, Seoul, South Korea

[2] Louis Dermatol Clin, Gyeonggi Do, South Korea

来源：

DERMATOLOGIC THERAPY | 2018年 / 31卷 / 05期

关键词：

brimonidine; laser; postinflammatory hyperpigmentation; MANAGEMENT;

D O I：

10.1111/dth.12657

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Brimonidine gel, originally approved for the treatment of facial rosacea, causes direct vasoconstriction and possesses extensive utilization in dermatologic fields. A Q-switched (QS) neodymium-doped yttrium aluminum garnet (Nd:YAG) laser is generally used to treat solar lentigo (SL), often leaving unwanted postinflammatory hyperpigmentation (PIH), especially in dark-skinned individuals. A 58-year-old man with Fitzpatrick skin type IV presented to remove solar lentigines from his face. Prior to and after laser treatment, topical brimonidine gel and steroid cream were applied. In this study, we investigated whether topical application of the alpha-adrenergic receptor agonist brimonidine could reduce PIH after QS laser treatment of lentigine in a dark-skinned patient.

引用

页数：3

共 8 条

[1] Brimonidine tartrate 0.33% gel for the management of posttreatment erythema induced by laser skin resurfacing [J].